Management of hereditary dyslipidaemia; the paradigm of autosomal dominant hypercholesterolaemia

European Journal of Human Genetics

Volumn 13, Issue 12, 2005, Pages 1247-1253

  Fouchier, Sigrid W ^a   Rodenburg, Jessica ^a   Defesche, Joep C ^a   Kastelein, John P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ADH; FDB; FH; IMT; Population; Screening

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; AUTOSOMAL DOMINANT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DYSLIPIDEMIA; GENETIC DISORDER; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MASS SCREENING; MOLECULAR GENETICS; PATIENT CARE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION;

DYSLIPIDEMIAS; GENES, DOMINANT; HUMANS; HYPERLIPOPROTEINEMIA TYPE II;

EID: 30744476550     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201496     Document Type: Review

References (54)

1. Goldstein JL, Hobbs HH, Brown MS, Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001, pp 2863-2913.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
3. Grundy SM, Cleeman JI, Merz CN et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732.
4. Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-112.
5. LDL-Receptor Gene in FH - Mutation Database http://www.ucl.ac.uk/fh.
6. UMD-LDL-receptor Database http://www.umd.necker.fr.
7. Defesche JC, Pricker KL, Hayden MR et al: Familial defective apolipoprotein B-100 is clinically indistiguishable from familial hypercholesterolemia. Arch Intern Med 1993; 153: 2349-2356.
8. Fouchier SW, Defesche JC, Umans-Eckenhausen MAW et al: The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001; 109: 602-615.
9. Abifadel M, Varret M, Rabes JP et al: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156.
10. Leren TP: Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004; 65: 419-422.
11. Timms KM, Wagner S, Samuels ME et al: A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114: 349-353.
12. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH: Low LDL-cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet, published online 16 January 2005; doi 10.1038/ng1509.
13. Edwards JE, Moore RA: StatinA in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4: 18.
14. Pearson TA, Laurora I, Chu H et al: The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
15. Marcelino JJ, Feingold KR: Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610.
16. Schectman G, Hiatt J: Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204.
17. Schrott HG, Bittner V, Vittinghoff E et al: Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997; 277: 1281-1286.
18. Smilde TJ, Van Wissen S, Wollersheim H et al: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581.
19. Taylor AJ, Kent SM, Flaherty PJ et al: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-2060.
20. Schwartz GG, Bolognese MA, Tremblay BP et al: Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. Am Heart J 2004; 148: E4.
21. Gagne C, Bays HE, Weiss SR et al: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-1091.
22. Kerzner B, Corbelli J, Sharp S et al: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-424.
23. Davidson MH, McGarry T, Bettis R et al: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134.
24. Feldman T, Koren M, Insull Jr W et al: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-1486.
25. Ballantyne CM, Houri J, Notarbartolo A et al: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
26. Lusis AJ: Atherosclerosis. Nature 2000; 407: 233-241.
27. De Groot E, Hovingh GK, Wiegman A et al: Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109: III33-III38.
28. Blankenhorn DH, Hodis HN: George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177-192.
29. Bots ML, Hoes AW, Koudstaal PJ et al: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-1437.
30. Heiss G, Sharrett AR, Barnes R et al: Carotid atherosclerosis measured by B-mode ultrasound in populations: Associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134: 250-256.
31. Van Dam MJ, de Groot E, Clee SM et al: Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: An observational study. Lancet 2002; 359: 37-42.
32. Crouse III JR, Byington RP, Bond MG et al: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-459.
33. Salonen R, Nyyssonen K, Porkkala E et al: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-1764.
34. MacMahon S, Sharpe N, Gamble G et al: Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784-1790.
35. Jukema JW, Bruschke AV, van Boven AJ et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
36. Furberg CD, Adams Jr HP, Applegate WB et al: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-1687.
37. Blankenhorn DH, Azen SP, Kramsch DM et al: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-976.
38. Smilde TJ, Van den Berkmortel FW, Wollersheim H et al: The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000; 30: 473-480.
39. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJ: Familial hypercholesterolemia in children. Curr Opin Lipidol 2004; 15: 405-411.
40. Wiegman A, Rodenburg J, de Jongh S et al: Family history and cardiovascular risk in familial hypercholesterolemia: Data in more than 1000 children. Circulation 2003; 107: 1473-1478.
41. American Academy of Pediatrics Committee on Nutrition: Statement on cholesterol: Pediatrics 1992; 90: 469-473.
42. Tonstad S, Knudtzon J, Sivertsen M et al: Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129: 42-49.
43. Stein EA, Illingworth DR, Kwiterovich Jr PO et al: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial. JAMA 1999; 281: 137-144.
44. Knipscheer HC, Boelen CC, Kastelein JJ et al: Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867-871.
45. McCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 143: 74-80.
46. De Jongh S, Ose L, Szamosi T et al: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106: 2231-2237.
47. Wiegman A, Hutten BA, de Groot E et al: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 2004; 292: 331-337.
48. De Jongh S, Lilien MR, Bakker HD et al: Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-197.
49. Tonstad S, Joakimsen O, Stensland-Bugge E et al: Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996; 16: 984-991.
50. Slyper AH: What vascular ultrasound testing has revealed about pediatric atherogenesis, and a potential clinical role for ultrasound in pediatric risk assessment. J Clin Endocrinol 2004; 89: 3089-3095.
51. Wiegman A, de Groot E, Hutten BA et al: Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-370.
52. De Jongh S, Lilien MR, Op 't Rood J et al: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117-2121.
53. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ et al: Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165-168.
54. Umans-Eckenhausen MA, Defesche JC, van Dam MJ et al: Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163: 65-68.